Home > Investors
2018 News and Events
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
05/07/18The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke
Inclisiran reduced key atherogenic lipoproteins – found in the blood of individuals at high risk of heart attacks – back to normal in 68% to 90% of patient studied Inclisiran drove sustained lowering of key atherogenic lipoproteins – non-HDL-C, ApoB, VLDL-C and Lp(a) Pre-specified analysis of ORION-1 Phase II study featured in late-breaking session at 86th Annual European Atherosclerosis Society Congress Analysis acc... 
Printer Friendly Version
04/30/18The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions
–Data shows inclisiran has a one-size-fits-all dosing regimen of 300 mg on Day-1, Day-90 and every six months thereafter across a wide range of dyslipidemia patient populations and sub-groups– PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 30, 2018-- The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las ... 
Printer Friendly Version
04/25/18The Medicines Company Reports First-Quarter 2018 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 25, 2018-- The Medicines Company (NASDAQ: MDCO) today reported its financial results for the first quarter ended March 31, 2018. “During the first quarter of 2018, The Medicines Company continued to demonstrate strong clinical and operational execution, significantly advancing the ORION development programs for our investigational agent, inclisiran, and delivering against all of our other 2018 objectives,” ... 
Printer Friendly Version
04/19/18The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 19, 2018-- The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.m., Eastern Time, to discuss first-quarter 2018 financial results and operational developments. The conference call may be accessed by telephone as follows: U.S./Canada:     ... 
Printer Friendly Version
03/27/18The Medicines Company Announces Chief Financial Officer Transition
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 27, 2018-- The Medicines Company (NASDAQ: MDCO) today announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately. Mr. Visioli succeeds William B. O’Connor, who is retiring from the Company after serving as Chief Accounting Officer and then Chief Financial Officer for a total of 13 years. Mr. O’Connor will remain with the Company as an advisor thro... 
Printer Friendly Version
03/16/18The Medicines Company to Participate in the Oppenheimer 28th Annual Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 16, 2018-- The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018, in New York City, NY. The Company is scheduled to present at 08:00 a.m., Eastern Time. A live audio webcast will be available in the “Investors-Events/Presentations” section of The Medicines Company website. A replay of the presentati... 
Printer Friendly Version
03/08/18The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule
ORION-10, a Phase III pivotal clinical trial conducted in the United States completed randomization of more than 1,500 patients in 12 weeks – 10 weeks ahead of schedule All pivotal LDL-C lowering trials with 18 months follow up (ORION-9, ORION-10 and ORION-11) have now completed enrollment with data read-out expected in Q3/2019 PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 8, 2018-- The Medicines Company (NA... 
Printer Friendly Version
03/08/18The Medicines Company to Participate in the Cowen 38th Annual Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 8, 2018-- The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Cowen 38th Annual Health Care Conference on Tuesday, March 13, 2018, in Boston, MA. The Company is scheduled to present at 10:00 a.m., Eastern Time. A live audio webcast will be available in the “Investors-Events/Presentations” section of The Medicines Company website. A replay of the presentation will be ... 
Printer Friendly Version
02/27/18The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 27, 2018-- The Medicines Company (NASDAQ: MDCO) today announced that its Board of Directors has appointed Dr. Sarah Schlesinger as a new, independent Director of the Company, effective immediately. Dr. Schlesinger has spent more than 20 years working in the field of cellular immunity. She is currently the Chair of The Rockefeller University Hospital’s Institutional Review Board (IRB) and Senior Physi... 
Printer Friendly Version
02/21/18The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 21, 2018-- The Medicines Company (NASDAQ:MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2017. “We have successfully executed our strategic action plan for 2017 by divesting our non-core assets, restructuring our business to focus on inclisiran, and initiating the inclisiran Phase 3 ORION program – recently completing target enrollment ahead of schedule in ... 
Printer Friendly Version
02/20/18The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule
ORION-9, a Phase III confirmatory clinical trial in heterozygous familial hypercholesterolemia patients randomized more than 400 patients in 10 weeks – 14 weeks ahead of schedule PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 20, 2018-- The Medicines Company (NASDAQ: MDCO) today announced that the target of 400 patients randomized in the ORION-9 trial has been exceeded in 10 weeks – considerably ahead of its anticipated recruitment goal of 24 ... 
Printer Friendly Version
02/14/18The Medicines Company to Host Conference Call and Webcast Discussing Fourth-Quarter and Full-Year 2017 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 14, 2018-- The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Wednesday, February 21, 2018, at 8:30 a.m., Eastern Time, to discuss fourth-quarter and full-year 2017 financial results and operational developments. The conference call may be accessed by telephone as follows:   U.S./Canada: ... 
Printer Friendly Version
02/08/18The Medicines Company to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 8, 2018-- The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018, in New York City. Clive Meanwell, M.D., Ph.D., Chief Executive Officer, will participate in a fireside chat at 9:00 a.m., Eastern Time. A live audio webcast will be available in the “Investors-Events/Presentations” sect... 
Printer Friendly Version
01/25/18Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule
– ORION-11, a Phase III confirmatory clinical trial randomized more than 1,500 patients in 11 weeks – FDA grants Orphan Drug Designation to inclisiran for the treatment of homozygous familial hypercholesterolemia (HoFH) – Following encouraging Phase II data, a Phase III clinical trial of inclisiran in HoFH set to begin in 2018 – PARSIPPANY, N.J. – January 25, 2018 – The Medicines Company (NASDAQ: MDCO) today announced that the target of 1,500 patients randomized in the ORION-11 t... 
Printer Friendly Version
01/08/18The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 8, 2018-- The Medicines Company (NASDAQ:MDCO) today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for consideration consisting of $215 million of guaranteed cash, approximately 3.3 million shares of Melinta common stock, tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin® IV, and the assumpti... 
Printer Friendly Version
01/03/18The Medicines Company to Present at the 36th Annual J. P. Morgan Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 3, 2018-- The Medicines Company (NASDAQ:MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.D., Ph.D., will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018, at 8:30 a.m., Pacific Time, at The Westin St. Francis in San Francisco, CA. A Q&A breakout session will immediately follow the presentation at 9:00 a.m., Pacific Time. A live audio... 
Printer Friendly Version